BioAge Labs Inc公布BGE-102一期临床试验积极中期数据,计划2026年上半年启动2a期试验

美股速递
Mar 24

生物制药公司BioAge Labs Inc近日披露了其候选药物BGE-102的一期临床试验积极中期结果。数据显示,该药物在安全性及耐受性方面表现良好,为后续临床开发奠定基础。

公司宣布,基于当前数据进展,计划于2026年上半年启动针对特定适应症的2a期临床试验。这一时间表反映出企业正按既定战略推进该药物的临床开发进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10